Skip to main content

Bruker Reports Preliminary Q1 Revenues of $549M to $554M, Beating Analyst Expectations

NEW YORK – Bruker announced after the close of the market on Tuesday that it anticipates Q1 2021 revenues of $549 million to $554 million, which would represent year-over-year growth of approximately 30 percent to 31 percent.

On average, analysts are expecting Q1 revenues of $506.9 million.

The company said the performance was driven by double-digit organic year-over-year revenue growth across all three of its Bruker Scientific Instrument groups, including the placement of two GHz-class NMR systems.

Bruker estimated non-GAAP organic revenue growth of 22 percent to 23 percent for Q1 2021, up from its previous projection of greater than 15 percent organic growth for the quarter.

In Wednesday morning trading on Nasdaq, Bruker shares were up a fraction of a percent to $69.14.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.